2023
Cardiology Encounters for Underrepresented Racial and Ethnic Groups with Human Immunodeficiency Virus and Borderline Cardiovascular Disease Risk
Bloomfield G, Hill C, Chiswell K, Cooper L, Gray S, Longenecker C, Louzao D, Marsolo K, Meissner E, Morse C, Muiruri C, Thomas K, Velazquez E, Vicini J, Pettit A, Sanders G, Okeke N. Cardiology Encounters for Underrepresented Racial and Ethnic Groups with Human Immunodeficiency Virus and Borderline Cardiovascular Disease Risk. Journal Of Racial And Ethnic Health Disparities 2023, 11: 1509-1519. PMID: 37160576, PMCID: PMC10632543, DOI: 10.1007/s40615-023-01627-0.Peer-Reviewed Original ResearchBody mass indexCVD riskCardiovascular diseaseCVD risk factor managementCox proportional hazards regressionHigher body mass indexUrban residenceRisk factor managementCardiovascular disease riskHuman immunodeficiency virusProportional hazards regressionAssociation of patientHigh-risk individualsAcademic medical centerAmbulatory visitsMedian ageMass indexProvider factorsAtrial fibrillationHazards regressionImmunodeficiency virusResultsA totalFactor managementInsurance typeMedical Center
2017
Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya
Temu TM, Lane KA, Shen C, Ng'ang'a L, Akwanalo CO, Chen PS, Emonyi W, Heckbert SR, Koech MM, Manji I, Vatta M, Velazquez EJ, Wessel J, Kimaiyo S, Inui TS, Bloomfield GS. Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya. PLOS ONE 2017, 12: e0185204. PMID: 28934312, PMCID: PMC5608343, DOI: 10.1371/journal.pone.0185204.Peer-Reviewed Original ResearchConceptsValvular AFValvular heart diseaseAtrial fibrillationNVAF patientsAF patientsHeart diseaseNon-valvular atrial fibrillationGlobal cardiovascular disease burdenValvular atrial fibrillationRates of hypertensionCardiovascular disease burdenLong-term outcomesProspective data collectionAnticoagulation therapyClinical characteristicsCohort studyClinical profileHeart failureOverall mortalityClinical featuresComorbid conditionsFatal outcomeMean ageFemale sexDisease burdenIncidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation
Wyrembak J, Campbell KB, Steinberg BA, Bahnson TD, Daubert JP, Velazquez EJ, Samad Z, Atwater BD. Incidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation. The American Journal Of Cardiology 2017, 119: 1017-1022. PMID: 28153350, DOI: 10.1016/j.amjcard.2016.12.008.Peer-Reviewed Original ResearchConceptsRoutine transesophageal echocardiographyAtrial appendage thrombusLAA thrombusTransesophageal echocardiographyVASc scoreAppendage thrombusNonvitamin K oral anticoagulantsLeft atrial appendage thrombusSingle-center retrospective studyLower LAA velocityTEE-related complicationsOral anticoagulant therapyAtrial fibrillation ablationLAA velocityNOAC therapyOral anticoagulantsAF ablationAnticoagulant therapyCatheter ablationFibrillation ablationAtrial fibrillationRetrospective studyTEE procedureLower incidenceNOACs
2015
Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs
DeVore AD, Schulte PJ, Mentz RJ, Hardy NC, Kelly JP, Velazquez EJ, Maya JF, Kielhorn A, Patel HK, Reed SD, Hernandez AF. Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. The American Journal Of Cardiology 2015, 117: 946-951. PMID: 26805662, PMCID: PMC5429586, DOI: 10.1016/j.amjcard.2015.12.031.Peer-Reviewed Original ResearchConceptsBeats/minReduced ejection fractionElevated heart rateHeart rateHeart failureEjection fractionΒ-blockersMedical costsHospital cost accounting dataLarge tertiary care centerMortality/hospitalizationTertiary care centerOne-year outcomesDirect medical costsNational death recordsRoutine clinical practiceMedian heart rateProportional hazards modelDuke University HospitalHeart rate assessmentElectronic medical recordsCause mortalityEligible patientsMultivariate adjustmentAtrial fibrillationGenetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL)
Bloomfield GS, Temu TM, Akwanalo CO, Chen PS, Emonyi W, Heckbert SR, Koech MM, Manji I, Shen C, Vatta M, Velazquez EJ, Wessel J, Kimaiyo S, Inui TS. Genetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL). American Heart Journal 2015, 170: 455-464.e5. PMID: 26385028, PMCID: PMC4575772, DOI: 10.1016/j.ahj.2015.06.008.Peer-Reviewed Original ResearchConceptsValvular atrial fibrillationNonvalvular atrial fibrillationValvular heart diseaseAtrial fibrillationHeart diseaseCurrent tobacco smokingHistory of strokeCase-control studyGroup morbidityGenetic associationTobacco smokingSaharan AfricaMean ageAfrican patientsCardiovascular diseaseClinical phenotypingFibrillationPrimary analysisPatientsControl populationGenetic testingMorbidityDiseaseGenetic mutationsMost participantsOutcomes After Nonemergent Electrical Cardioversion for Atrial Arrhythmias
Steinberg BA, Schulte PJ, Hofmann P, Ersbøll M, Alexander JH, Broderick-Forsgren K, Anstrom KJ, Granger CB, Piccini JP, Velazquez EJ, Shah BR. Outcomes After Nonemergent Electrical Cardioversion for Atrial Arrhythmias. The American Journal Of Cardiology 2015, 115: 1407-1414. PMID: 25784514, PMCID: PMC4414802, DOI: 10.1016/j.amjcard.2015.02.030.Peer-Reviewed Original ResearchConceptsElectrical cardioversionAtrial arrhythmiasTEE useTransesophageal Echocardiography UseTertiary care centerBetter clinical outcomesCHADS2 scoreRehospitalization ratesProcedural complicationsClinical outcomesAtrial fibrillationRhythm controlAtrial flutterSinus rhythmEchocardiography useCare centerProcedural characteristicsECV successPatient's conditionHeart ratePatientsMultivariate analysisRehospitalizationCardioversionComplications
2014
Clinical outcome as a function of the PR-interval—there is virtue in moderation: data from the Duke Databank for cardiovascular disease
Holmqvist F, Thomas KL, Broderick S, Ersbøll M, Singh D, Chiswell K, Shaw LK, Hegland DD, Velazquez EJ, Daubert JP. Clinical outcome as a function of the PR-interval—there is virtue in moderation: data from the Duke Databank for cardiovascular disease. EP Europace 2014, 17: 978-985. PMID: 25164430, DOI: 10.1093/europace/euu211.Peer-Reviewed Original ResearchConceptsCoronary heart diseaseHeart diseaseDuke University Medical CenterMajor cardiovascular outcomesMajor cardiovascular eventsNative coronary arteriesUniversity Medical CenterPR interval durationCV eventsCardiovascular eventsCardiovascular outcomesCause mortalityCoronary angiographyDuke DatabankClinical outcomesAtrial fibrillationPoor outcomeCoronary arterySignificant stenosisSinus rhythmCardiovascular diseaseMedical CenterHigh riskPatientsRelevant covariates
2012
Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting
Han SY, Palmeri ST, Broderick SH, Hasselblad V, Rendall D, Stevens S, Tenaglia A, Velazquez E, Whellan D, Wagner G, Heitner JF. Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. Journal Of Electrocardiology 2012, 46: 45-50. PMID: 23063241, DOI: 10.1016/j.jelectrocard.2012.08.011.Peer-Reviewed Original ResearchConceptsNonvalvular atrial fibrillationQuality of anticoagulationAtrial fibrillationTherapeutic rangeStroke preventionPrimary careCardiology practiceRecent large randomized control trialsNew oral anticoagulation agentsPrimary care practice patientsCardiovascular disease risk factorsOne-year periodTreatment of AFInternational normalized ratio (INR) valuesLarge randomized control trialsOral anticoagulation agentsMean therapeutic rangeOral anticoagulation therapyDisease risk factorsPrimary care practicesNovel pharmacologic agentsMulti-center studyCurrent clinical practiceRandomized control trialPrimary care groups
2010
Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial
Nilsson KR, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, Kober L, Granger CB, Lewis EF, McMurray JJ, Califf RM, Velazquez EJ. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart 2010, 96: 838. PMID: 20406769, DOI: 10.1136/hrt.2009.180182.Peer-Reviewed Original ResearchConceptsRhythm control strategyAcute Myocardial Infarction trialMyocardial Infarction trialAtrial fibrillationMyocardial infarctionRate control strategyEarly mortalityAnti-arrhythmic drug therapyTreatment of AFPeri-infarct periodIncidence of strokeManagement of patientsRisk of deathLate mortalityPatient populationDrug therapyCox modelPatientsMortalityInfarctionStrokeValsartanTrialsDeathDays
2006
Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction☆
Køber L, Swedberg K, McMurray JJ, Pfeffer MA, Velazquez EJ, Diaz R, Maggioni AP, Mareev V, Opolski G, Van de Werf F, Zannad F, Ertl G, Solomon SD, Zelenkofske S, Rouleau J, Leimberger JD, Califf RM. Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction☆. European Journal Of Heart Failure 2006, 8: 591-598. PMID: 16507350, DOI: 10.1016/j.ejheart.2005.11.007.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAngiotensin II Type 1 Receptor BlockersAtrial FibrillationCaptoprilCardiac Output, LowFemaleHumansMaleMiddle AgedMyocardial InfarctionOutcome Assessment, Health CarePrognosisProportional Hazards ModelsRisk AssessmentRisk FactorsSurvival AnalysisTetrazolesTime FactorsValineValsartanVentricular Dysfunction, LeftConceptsAcute myocardial infarctionCurrent atrial fibrillationPrior atrial fibrillationHeart failureAtrial fibrillationRisk of deathMyocardial infarctionCV eventsGreater long-term mortalityMajor CV eventsPrior heart failureAdverse CV eventsMajor cardiovascular eventsVentricular systolic dysfunctionLong-term mortalityHR of deathMajor risk indicatorsCardiovascular eventsSystolic dysfunctionVentricular dysfunctionPrimary outcomeVALIANT trialPatientsLVSDInfarction